Aptose Biosciences Inc , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
infoAptose Biosciences is a micro cap stock with a total market cap of 28.21M.
infoThey trade on the NASDAQ and had their IPO 31 years and 5 months ago.
infoAptose Biosciences currently employs 35 people.
infoAs of Wednesday, Aug 23 2023, Aptose Biosciences’s share price is $4.14.
News Relating to Aptose Biosciences
Seeking Alpha
Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript
Thursday Aug 10 2023 at 23:01
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications and Investor Relations William Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler Matthew Biegler – Oppenheimer Li Watsek – Cantor Fitzgerald Soumit Roy – JonesTrading Anish Nikhanj – RBC Capital Markets Operator Good afternoon. My name is Zeda and I will be your conference operator today.
InvestorPlace
3 Stocks With 1,000% Upside Potential
Sunday May 21 2023 at 10:03
If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.
Seeking Alpha
Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript
Monday May 08 2023 at 21:22
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler & Co. Li Watsek – Cantor Fitzgerald Joseph Pantginis – H.C.
GlobeNewsWire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
Thursday May 04 2023 at 07:01
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2023 Global Healthcare Conference on May 17, 2023.
GlobeNewsWire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
Monday Apr 24 2023 at 07:01
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update.
GlobeNewsWire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
Monday Apr 10 2023 at 16:01
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
Pulse2
Aptose Biosciences Announces Q4 And FY 2022 Results
Friday Mar 24 2023 at 14:20
Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update. The post Aptose Biosciences Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.
Seeking Alpha
Aptose Biosciences Inc. (APTO) Q4 2022 Earnings Call Transcript
Thursday Mar 23 2023 at 22:07
Aptose Biosciences Inc. (NASDAQ:APTO ) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Managing Director William Rice – Chairman, President and CEO Fletcher Payne – SVP and Chief Financial Officer Rafael Bejar – SVP and Chief Medical Officer Conference Call Participants Matthew Biegler – Oppenheimer Soumit Roy – Jones Trading Joe Pantginis – H.C. Wainwright Edward Tenthoff – Piper Sandler Operator Hello and thank you for standing by and welcome to Aptose Biosciences reports for the Fourth Quarter and Yearend 2022 Conference Call.
GlobeNewsWire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
Thursday Mar 09 2023 at 16:05
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update.
GlobeNewsWire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
Thursday Mar 02 2023 at 07:30
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.
GlobeNewsWire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
Wednesday Dec 28 2022 at 07:30
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA.
Seeking Alpha
Aptose Biosciences Inc. (APTO) Q3 2022 Earnings Call Transcript
Tuesday Nov 01 2022 at 19:52
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Pietropaolo – Managing Director William Rice – Chairman, President and CEO Fletcher Payne – SVP and Chief Financial Officer Rafael Bejar – SVP and Chief Medical Officer Conference Call Participants Li Watsek – Cantor Fitzgerald Soumit Roy – Jones Trading John Newman – Canaccord Genuity Matthew Biegler – Oppenheimer Joe Pantginis – H.C. Wainwright Edward Tenthoff – Piper Sandler Operator Good afternoon.
GlobeNewsWire
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
Tuesday Oct 18 2022 at 16:01
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September 30, 2022, on Tuesday, November 1, 2022 after the close of the market, and provide a corporate update.
GlobeNewsWire
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tuesday Aug 30 2022 at 07:30
SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City.
Seeking Alpha
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 02 2022 at 21:00
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Susan Pietropaolo – Managing Director William Rice – Chairman, President and CEO Fletcher Payne – SVP and Chief Financial Officer Rafael Bejar – SVP and Chief Medical Officer Conference Call Participants Matthew Biegler – Oppenheimer Li Watsek – Cantor Fitzgerald Edward Tenthoff – Piper Sandler Soumit Roy – Jones Trading John Newman – Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Aptose Biosciences Inc. Reports Result for the Second Quarter 2022.
GlobeNewsWire
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
Wednesday Jul 27 2022 at 07:30
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference, and Dr. Rice will present at the Conference:
Seeking Alpha
Aptose Biosciences Continues To Drift Without Thesis-Changing Data
Tuesday Jul 19 2022 at 18:31
Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of ‘239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023.
GlobeNewsWire
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
Tuesday Jul 19 2022 at 16:01
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update.
Seeking Alpha
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results – Earnings Call Transcript
Monday May 09 2022 at 22:00
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. William G. Rice – Chairman, President and Chief Executive Officer Dr. Rafael Bejar – Senior Vice President and Chief Medical Officer Dan Ferry – Managing Director, LifeSci Advisors LLC Conference Call Participants Gregory Renza – RBC Capital Markets Matthew Biegler – Oppenheimer & Co. Inc. Li Watsek – Cantor Fitzgerald Matthew Cross – Allegiance Global Partners Operator Welcome to the Aptose Biosciences o Incorporated Reports Result for the First Quarter 2022 Conference Call.
GlobeNewsWire
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
Tuesday May 03 2022 at 07:30
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate in the RBC Capital Markets Global Healthcare Conference:
GlobeNewsWire
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
Monday Apr 25 2022 at 07:30
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update.
GlobeNewsWire
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
Thursday Mar 31 2022 at 07:30
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias (AML) at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference:
Seeking Alpha
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results – Earnings Call Transcript
Tuesday Mar 22 2022 at 20:24
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results – Earnings Call Transcript
GlobeNewsWire
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
Tuesday Mar 08 2022 at 07:30
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update.
GlobeNewsWire
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
Tuesday Mar 01 2022 at 07:30
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference:
Zacks Investment Research
5 Beaten-Down Biotech Bets to Bounce Back in 2022
Friday Dec 31 2021 at 15:18
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Benzinga
Aptose Shares Fall After Ceasing APTO-253 Program
Monday Dec 20 2021 at 09:08
Aptose Biosciences Inc (NASDAQ: APTO) will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors. The decision follows the prioritization of the Company’s other more advanced pipeline candidates, as well as an internal review of APTO-253, including an FDA clinical hold.
Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Tuesday Dec 14 2021 at 07:38
Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in patients relapsed or refractory acute myeloid leukemia (AML) who had received at least one prior line of therapy. Data were presented at the American Society of Hematology (ASH) Annual meeting.
Zacks Investment Research
Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options
Friday Nov 26 2021 at 11:28
Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.
GlobeNewsWire
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
Monday Nov 22 2021 at 16:02
SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the Piper Sandler 33rd Annual Healthcare Conference, being held virtually.
Aptose Biosciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Aptose Biosciences’s Altman Z-score is -4.16 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Aptose Biosciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Aptose Biosciences.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Aptose Biosciences’s Income Quality of 0.85 is greater than its Industry Group of 0.69 (23.2% greater)
Aptose Biosciences’s Income Quality of 0.85 is greater than its Major Industry Group of 0.71 (19.7% greater)
Aptose Biosciences’s Income Quality of 0.85 is greater than its Sector of 0.75 (13.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Aptose Biosciences’s Current Ratio of 2.11 is lower than its Industry Group of 4.76 (-55.7% lower)
Aptose Biosciences’s Current Ratio of 2.11 is lower than its Major Industry Group of 4.32 (-51.2% lower)
Aptose Biosciences’s Current Ratio of 2.11 is lower than its Sector of 2.6 (-18.8% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.6 & -1.27)
Cannot compare a negative PE Ratio (-0.6 & -1.1)
Cannot compare a negative PE Ratio (-0.6 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Aptose Biosciences’s PB Ratio of 2.05 is greater than its Industry Group of 1.34 (53.0% greater)
Aptose Biosciences’s PB Ratio of 2.05 is greater than its Major Industry Group of 1.4 (46.4% greater)
Aptose Biosciences’s PB Ratio of 2.05 is greater than its Sector of 1.62 (26.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aptose Biosciences’s ROE of -3.42 is lower than its Industry Group of -0.44 (-677.3% lower)
Aptose Biosciences’s ROE of -3.42 is lower than its Major Industry Group of -0.38 (-800.0% lower)
Aptose Biosciences’s ROE of -3.42 is lower than its Sector of -0.03 (-11300.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Aptose Biosciences’s ROCE of -3.34 is lower than its Industry Group of -0.42 (-695.2% lower)
Aptose Biosciences’s ROCE of -3.34 is lower than its Major Industry Group of -0.37 (-802.7% lower)
Aptose Biosciences’s ROCE of -3.34 is lower than its Sector of -0.04 (-8250.0% lower)
Derived from SEC.GOV filing dataopen_in_new